Zeke Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Zeke Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,456	Closed	-$422K	–	339
2021 Q1	$422K	Sell	1,456 -179	-11%	-$49.8K	0.03%	154
2020 Q4	$409K	Buy	1,635 +324	+25%	+$77.2K	0.03%	148
2020 Q3	$297K	Sell	1,311 -140	-10%	-$29.1K	0.03%	161
2020 Q2	$253K	Buy	+1,451	New	+$232K	0.05%	161
2020 Q1	–	Sell	-4,512	Closed	-$689K	–	299
2019 Q4	$689K	Hold	4,512	–	–	0.06%	301
2019 Q3	$597K	Hold	4,512	–	–	0.05%	326
2019 Q2	$640K	Hold	4,512	–	–	0.06%	293
2019 Q1	$655K	Sell	4,512 -4,182	-48%	-$549K	0.06%	299
2018 Q4	$984K	Buy	+8,694	New	+$1.09M	0.09%	204

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Zeke Capital Advisors's CRL Position: Q2 2021 in Review

Zeke Capital Advisors sold out of Charles River Laboratories (CRL) in Q2 2021, closing a stake of 1,456 shares — an estimated $422K sold.

Zeke Capital Advisors first reported a position in CRL in Q4 2018 and held it in 9 quarters. The position peaked at $984K in Q4 2018. 639 funds tracked by Wall St. Rank hold CRL as of Q2 2021.

Zeke Capital Advisors reported no remaining Charles River Laboratories position as of Q2 2021 after selling out during the quarter.
Zeke Capital Advisors sold 1,456 Charles River Laboratories shares in Q2 2021, an estimated $422K.
Zeke Capital Advisors first reported a position in Charles River Laboratories in Q4 2018 and held it in 9 quarters.
Zeke Capital Advisors's Charles River Laboratories position peaked at $984K in Q4 2018.
639 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2021.

Based on Zeke Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.